Impact of Oxidative Stress and Antiepileptic Drug Treatment on Oxidative Markers in Children with Newly Diagnosed Idiopathic Epilepsy: A Comparative Study of Valproate and Oxcarbazepine
Keywords:
Oxidative stress, Epilepsy, Nitric oxide (NO), Xanthine oxidase (XO), Malondialdehyde (MDA), Valproate (VPA), Oxcarbazepine (OXC), Antiepileptic drugs (AEDs), Pediatric epilepsyAbstract
This study investigates the role of oxidative stress in newly diagnosed idiopathic epilepsy and the effects of antiepileptic drugs (AEDs), specifically valproate (VPA) and oxcarbazepine (OXC), on oxidative stress markers, including nitric oxide (NO), xanthine oxidase (XO), and malondialdehyde (MDA). Seventy-five children (32 girls and 43 boys, aged 5-12 years) with newly diagnosed epilepsy and 15 healthy controls were included. The patients were divided into three treatment groups: 26 treated with VPA, 26 treated with OXC, and 23 treated with other AEDs. Blood samples were collected before treatment and at 3 and 6 months after treatment to measure NO, XO, and MDA levels. At baseline, NO concentrations were significantly higher in epileptic children compared to controls (p = 0.002). No significant differences were observed in XO or MDA levels between groups at baseline (p = 0.231 and p = 0.636, respectively). After 3 months, MDA levels decreased significantly in both the VPA and OXC groups, with continued reduction at 6 months. In contrast, MDA levels remained unchanged in the control group. NO levels also decreased significantly in both VPA and OXC groups at 6 months. High XO concentrations were observed in both medication groups over the study period. In conclusion, this study highlights elevated oxidative stress in children with idiopathic epilepsy and suggests that both VPA and OXC reduce oxidative stress markers, with OXC showing a greater reduction in MDA. Further studies with larger sample sizes and placebo controls are needed to confirm the antioxidant effects of OXC in pediatric epilepsy.
Downloads
References
Patel, M.N. (2002). Oxidative stress, mitochondrial dysfunction, and epilepsy. Free Radical Research, 36, 1139-1146.
Erakovic, V., Zupan, G., & Varljen, J. (2001). Altered activities of rat brain metabolic enzymes in electroconvulsive shock-induced seizures. Epilepsia, 42, 181-189.
Rauca, C., Zerbe, R., & Jantze, H. (1999). Formation of free hydroxyl radicals after pentylenetetrazol-induced seizure and kindling. Brain Research, 847, 347-351.
Bruce, A.J., & Baudry, M. (1995). Oxygen free radicals in rat limbic structures after kainate-induced seizures. Free Radical Biology and Medicine, 18, 993-1002.
Iadecola, C. (1997). Bright and dark sides of NO in ischemic brain injury. Trends in Neurosciences, 20, 132-139.
Szabo, C. (1991). Physiological and pathophysiological roles of NO in the central nervous system. Brain Research Bulletin, 41, 131-141.
Wojtal, K., Gniatkowska-Wwakowska, A., & Czuczwar, S.J. (2003). Is nitric oxide involved in the anticonvulsant action of antiepileptic drugs? Polish Journal of Pharmacology, 55, 535-542.
Yuksel, A., Cengiz, M., Seven, M., et al. (2001). Changes in the antioxidant system in epileptic children receiving antiepileptic drugs: two year prospective studies. Journal of Child Neurology, 16, 603-606.
Michoulas, A., Tong, V., Teng, X.W., et al. (2006). Oxidative stress in children receiving valproic acid. Journal of Pediatrics, 149, 692-696.
Verrotti, A., Scardapane, A., Franzoni, E., et al. (2008). Increased oxidative stress in epileptic children treated with valproic acid. Epilepsy Research, 78, 171-177.
Sobaniec, W., Solowiej, E., Kulak, W., et al. (2006). Evaluation of the influence of antiepileptic therapy on antioxidant enzyme activity and lipid peroxidation in erythrocytes of children with epilepsia. Journal of Child Neurology, 21, 558-562.
Cengiz, M., Yuksel, A., Seven, M. (2000). The effects of carbamazepine and VPA on the erythrocyte glutathione, glutathione peroxidase, superoxide dismutase and serum lipid peroxidation in epileptic children. Pharmacological Research, 41, 423-425.
Sołowiej, E., & Sobaniec, W. (2003). The effect of antiepileptic drug therapy on antioxidant enzyme activity and serum lipid peroxidation in young patients with epilepsy. Neurology and Neurochirurgia Polska, 37, 991-1003.
Bolayir, E., Celik, K., Tas, A., et al. (2004). The effects of OXC on oxidative stress in epileptic patients. Methods in Find Experimental Clinical Pharmacology, 26, 345-348.
Chang, T.K., & Abbott, F.S. (2006). Oxidative stress as a mechanism of valproic acid-associated hepatotoxicity. Drug Metabolism Reviews, 38, 627-639.
Dam, M., Ekberg, R., Løyning, Y., et al. (1989). A double-blind study comparing OXC and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Research, 3, 70-76.
Schmidt, D., & Elger, C.E. (2004). What is the evidence that OXC and carbamazepine are distinctly different antiepileptic drugs? Epilepsy Behavior, 5, 627-635.
Beydoun, A., & Kutluay, E. (2002). OXC. Expert Opinion on Pharmacotherapy, 3, 59-71.
Commission on classification and terminology of the International League Against Epilepsy. (1989). Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia, 30, 389-399.
Scheuer, M.L., & Pedley, T.A. (1990). The evaluation and treatment of seizures: current concepts. New England Journal of Medicine, 323, 1468-1474.
Durak, I., Kavutcu, M., Kaçmaz, M., et al. (2001). Effects of isoflurane on NO metabolism and oxidant status of guinea pig myocardium. Acta Anaesthesiologica Scandinavica, 45, 119-122.
Devrim, E., Erten, S., & Erguder, I.B. (2008). MDA and NO levels in erythrocytes from patients with systemic sclerosis. Medical Principles and Practice, 17, 349-350.
Hashimoto, S. (1974). A new spectrophotometric assay method of XO in crude tissue homogenate. Analytical Biochemistry, 62, 426-435.
Dahle, L.K., Hill, E.G., & Holman, R.T. (1962). The thiobarbituric acid reaction and the autoxidations of polyunsaturated fatty acid methyl esters. Archives of Biochemistry and Biophysics, 98, 253-261.
Halliwell, B. (1992). Reactive oxygen species and the central nervous system. Journal of Neurochemistry, 59, 1609-1623.
Sandirasegarane, L., Mikler, J.R., Tuchek, J.M., et al. (1996). Enhanced forebrain NO synthase activity in epileptic fowl. Brain Research, 735, 311-313.
Ribeiro, L.R., Fighera, M.R., Oliveira, M.S., et al. (2009). Methylmalonate-induced seizures are attenuated in inducible NO synthase knockout mice. International Journal of Developmental Neuroscience, 27, 157-163.
de Vasconcelos, A. Pereira, Marescaux, C., & Nehlig, A. (1998). Age-dependent regulation of seizure activity by NO in the developing rat. Brain Research Developmental Brain Research, 107, 315-319.
Rundfeldt, C., Koch, R., & Richter, A. (1995). Dose-dependent anticonvulsant and proconvulsant effects of NO synthase inhibitors on seizure threshold in a cortical stimulation model in rats. European Journal of Pharmacology, 274, 73-81.
Royes, L.F., Fighera, M.R., Furian, A.F., et al. (2007). The role of NO on the convulsive behavior and oxidative stress induced by methylmalonate: an electroencephalographic and neurochemical study. Epilepsy Research, 73, 228-237.
Itoh, K., & Watanabe, M. (2009). Paradoxical facilitation of pentylenetetrazole-induced convulsion susceptibility in mice lacking neuronal NO synthase. Neuroscience, 159, 735-743.
Armstead, W.M., Mirro, R., & Leffer, C.W. (1989). Cerebral superoxide anion generation during seizures in newborn pigs. Journal of Cerebral Blood Flow and Metabolism, 9, 175-179.
Oliver, C.N., Starke-Reed, P.E., & Stadtman, E.R. (1990). Oxidative damage to brain proteins, loss of glutamine synthase activity, and production of free radicals during ischemia/reperfusion-induced injury to gerbil brain. Proceedings of the National Academy of Sciences USA, 87, 5144-5147.
Singh, R., & Pathak, D.N. (1990). Lipid peroxidation and glutathione peroxidase, glutathione reductase, superoxide dismutase, catalase, and glucose 6-phosphate dehydrogenase activities in FeCl3-induced epileptogenic foci in the rat brain. Epilepsia, 31, 15-26.
Yis, U., Seckin, E., & Kurul, S. (2009). Effects of epilepsy and VPA on oxidant status in children with idiopathic epilepsy. Epilepsy Research, 84, 232-237.
Finkel, T., & Holbrook, N.J. (2000). Oxidants, oxidative stress, and the biology of aging. Nature, 408, 239-247.
Jeding, I., Evans, P.J., & Akanmu, D. (1995). Characterization of the potential antioxidant and prooxidant actions of some neuroleptic drugs. Biochemical Pharmacology, 49, 359-365.
Cotariu, D., Evans, S., & Zaidman, J.L. (1990). Early changes in hepatic redox homeostasis following treatment with a single dose of valproic acid. Biochemical Pharmacology, 40, 589-593.
Michaelis, M., Michaelis, U.R., & Fleming, I. (2004). VPA inhibits angiogenesis in vitro and in vivo. Molecular Pharmacology, 65, 520-527.
Faradji, H., Rousset, C., & Debilly, G. (2000). Sleep and epilepsy: a key role for nitric oxide? Epilepsia, 41, 794-801.
Karabiber, H., Yakinci, C., & Durmaz, Y. (2004). Serum nitrite and nitrate levels in epileptic children using VPA or carbamazepine. Brain Development, 26, 15-18.
Czuczwar, S.J., Tutka, P., & Klonowski, P. (1999). N(G)-nitro-l-arginine impairs the anticonvulsive action of ethosuximide against pentylenetetrazol. European Journal of Pharmacology, 366, 137-142.
Nagatomo, I., Akasaki, Y., & Uchida, M. (2000). Effects of combined administration of zonisamide and VPA or phenytoin to NO production, nitrite levels, and zonisamide concentrations in the brain of seizure-susceptible EL mice. Brain Research Bulletin, 53, 211-218.
Tutka, P., Luszczki, J., & Kleinrok, Z. (2002). Molsidomine enhances the protective activity of valproate against
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
